Pharsight

Drugs that contain Triamcinolone Acetonide

1. Triesence patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8211880 NOVARTIS Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Mar, 2029

(4 years from now)

US8128960 NOVARTIS Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Dec, 2029

(5 years from now)

Market Authorisation Date: 29 November, 2007

Treatment: Visualization during vitrectomy procedures; Treatment of ophthalmic disorders

Dosage: INJECTABLE;INTRAVITREAL

More Information on Dosage

TRIESENCE family patents

Family Patents

2. Xipere patents expiration

XIPERE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8636713 BAUSCH AND LOMB INC Methods and devices for drug delivery to ocular tissue using microneedle
May, 2027

(3 years from now)

US9636332 BAUSCH AND LOMB INC Methods and devices for the treatment of ocular diseases in human subjects
Nov, 2033

(9 years from now)

US9937075 BAUSCH AND LOMB INC Apparatus and methods for ocular injection
May, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Oct 22, 2024

Market Authorisation Date: 22 October, 2021

Treatment: Treatment of macular edema associated with uveitis

Dosage: SUSPENSION;INJECTION

More Information on Dosage

XIPERE family patents

Family Patents

3. Zilretta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828440 PACIRA PHARMS INC Corticosteroids for the treatment of joint pain
Aug, 2031

(7 years from now)

US9555048 PACIRA PHARMS INC Corticosteroids for the treatment of joint pain
Aug, 2031

(7 years from now)

Market Authorisation Date: 06 October, 2017

Treatment: Method of treating pain or inflammation with an injectable controlled or sustained release formulation of triamcinolone acetonide

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR

More Information on Dosage

ZILRETTA family patents

Family Patents